دورية أكاديمية
Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma.
| العنوان: | Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma. |
|---|---|
| المؤلفون: | Lee HM; Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, VA, USA., Alder L; Department of Internal Medicine, Division of Division of Hematology, Oncology, and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA., Nguyen M; Department of Internal Medicine, Division of Division of Hematology, Oncology, and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA., Dougherty SC; Department of Internal Medicine, Division of Division of Hematology, Oncology, and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA., Qu Y; Department of Internal Medicine, Division of Division of Hematology, Oncology, and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA., Thacker LR; Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA., Poklepovic A; Department of Internal Medicine, Division of Division of Hematology, Oncology, and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA.; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. |
| المصدر: | Journal of gastrointestinal oncology [J Gastrointest Oncol] 2023 Jun 30; Vol. 14 (3), pp. 1378-1391. Date of Electronic Publication: 2023 May 11. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: AME Publishing Group Country of Publication: China NLM ID: 101557751 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2078-6891 (Print) Linking ISSN: 20786891 NLM ISO Abbreviation: J Gastrointest Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: Hong Kong : AME Publishing Group Original Publication: Hong Kong : Pioneer Bioscience Pub. Co. |
| مستخلص: | Background: Yttrium-90 (Y90) radioembolization is a catheter-based therapy for hepatocellular carcinoma (HCC). Multiple trials have evaluated the efficacy of Y90 in HCC; however, few have assessed long-term hepatic function. This study aimed to evaluate a clinical real-world experience of Y90 effectiveness and long-term impact on hepatic function. Methods: A single-center retrospective chart review was performed for patients with Child-Pugh (CP) class A or B who received Y90 for primary HCC between 2008 and 2016. Model for end-stage liver disease (MELD) and CP scores were calculated on the day of treatment and 1, 3, 6, 12, and 24 months post-procedure. Results: Of the 134 patients included, the mean age was 60 years old and median overall survival (OS) from date of diagnosis was 28 months [95% confidence interval (CI): 22.21-38.05]. Patients with CP class A (85%) had a median progression-free survival (PFS) of 3 months (95% CI: 2.99-5.55) and median OS of 17 months (95% CI: 9.59-23.10) from date of Y90 treatment compared to a median PFS of 4 months (95% CI: 2.07-8.28) and OS of 8 months (95% CI: 4.60-15.64) for patients with CP class B. MELD scores were significantly higher post-treatment than pre-treatment, with significant recovery at 24 months. No significant differences were seen between cancer stage and OS, while PFS and cancer stage did show difference between cancer stage 1 and 3 with longer median PFS seen in stage 1. Conclusions: While our study supports the literature for OS in Y90-treated patients, we found a shorter PFS in this population. This may reflect the differences between the utilization of RECIST in clinical trials and clinical radiology practice in determining progression. Significant factors associated with OS were age, MELD, CP scores and portal vein thrombosis (PVT). For PFS, CP score and stage at diagnosis were significant. Increasing MELD scores over time likely reflected a combination of radioembolization-induced liver disease, liver decompensation or progression of HCC. The downtrend at 24 months is likely due to long term survivors with significant benefit from therapy with no long-term complications from Y90. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-882/coif). The authors have no conflicts of interest to declare. (2023 Journal of Gastrointestinal Oncology. All rights reserved.) |
| References: | J Nucl Med. 1994 Oct;35(10):1637-44. (PMID: 7931662) Saudi J Gastroenterol. 2016 Sep-Oct;22(5):353-359. (PMID: 27748320) Hepatology. 2021 Jan;73 Suppl 1:4-13. (PMID: 32319693) BMJ. 2018 Jul 18;362:k2817. (PMID: 30021785) Chin Clin Oncol. 2017 Apr;6(2):21. (PMID: 28482674) Semin Intervent Radiol. 2011 Jun;28(2):246-51. (PMID: 22654272) J Surg Oncol. 1989 Nov;42(3):192-6. (PMID: 2811384) Lancet. 2022 Oct 15;400(10360):1345-1362. (PMID: 36084663) J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6. (PMID: 23632345) Am J Roentgenol Radium Ther Nucl Med. 1968 Mar;102(3):552-61. (PMID: 5639573) Am J Clin Oncol. 2015 Oct;38(5):495-501. (PMID: 24064753) Cardiovasc Intervent Radiol. 2018 Oct;41(10):1557-1565. (PMID: 29948005) J Vasc Interv Radiol. 2019 Dec;30(12):1915-1923. (PMID: 31353191) Ann Surg. 1965 Aug;162:267-78. (PMID: 14327011) J Nucl Med. 2000 Oct;41(10):1673-81. (PMID: 11037997) J Hepatol. 2018 Apr;68(4):724-732. (PMID: 29331342) Hepatology. 2010 Nov;52(5):1741-9. (PMID: 21038413) Sci Rep. 2021 Mar 18;11(1):6306. (PMID: 33737641) Exp Mol Med. 2020 Dec;52(12):1898-1907. (PMID: 33268834) Tech Vasc Interv Radiol. 2019 Jun;22(2):70-73. (PMID: 31079713) Hepatology. 2018 Jan;67(1):123-133. (PMID: 28802062) Radiology. 1989 Sep;172(3):857-60. (PMID: 2549567) Hepatology. 2018 Oct;68(4):1429-1440. (PMID: 29194711) J Natl Cancer Inst. 1951 Aug;12(1):107-31. (PMID: 14874125) J Clin Med. 2019 Jan 07;8(1):. (PMID: 30621040) Taehan Yongsang Uihakhoe Chi. 2022 Mar;83(2):331-343. (PMID: 36237934) Hepatology. 2013 May;57(5):1826-37. (PMID: 22911442) Oncology. 2013;84(5):311-8. (PMID: 23615394) Aust N Z J Surg. 1992 Feb;62(2):105-10. (PMID: 1586298) J Hepatol. 2013 Oct;59(4):753-61. (PMID: 23707371) Gastroenterology. 2010 Jan;138(1):52-64. (PMID: 19766639) |
| فهرسة مساهمة: | Keywords: Hepatocellular carcinoma (HCC); hepatic function; real-world practice; yttrium-90 (Y90) |
| تواريخ الأحداث: | Date Created: 20230712 Latest Revision: 20230718 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10331743 |
| DOI: | 10.21037/jgo-22-882 |
| PMID: | 37435218 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2078-6891 |
|---|---|
| DOI: | 10.21037/jgo-22-882 |